EMA’s Emergency Task Force (ETF) is improving its approach to scientific advice for the most promising medicines and vaccines under development for public health threats.
Under the new process, developers of medicines falling within the scope of the ETF’s activities, including medicines for antimicrobial resistance (AMR) and other health threats that have the potential to cause public health emergencies, can apply for combined scientific advice from EMA, as well as clinical trial and ethics experts at national level. As a result, requirements for clinical trials and marketing authorisation of medicines and vaccines for public health threats will be aligned at an early stage, which should lead to more rapid authorisation of clinical trials and of these medicines.